TRANSGENE SA (TNG.PA) Stock Price, Quote, News and Overview
EPA:TNG - Euronext Paris - Matif - FR0005175080 - Common Stock - Currency: EUR
TNG.PA Quote, Performance and Key Statistics
EPA:TNG (3/27/2025, 7:00:00 PM)
0.671
+0.01 (+1.05%)
The current stock price of TNG.PA is 0.671 EUR. In the past month the price decreased by -3.45%. In the past year, price decreased by -41.14%.
TNG.PA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1ABBV.MI | ABBVIE INC | 20.64 | 341.81B | ||
| 4AB.DE | ABBVIE INC | 19.97 | 330.76B | ||
| AMG.DE | AMGEN INC | 15.46 | 152.54B | ||
| GIS.DE | GILEAD SCIENCES INC | 24.07 | 128.02B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 1730.74 | 120.00B | ||
| ARGX.BR | ARGENX SE | 344.87 | 33.53B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.12B | ||
| IDP.DE | BIOGEN INC | 8.51 | 19.03B | ||
| 1MRNA.MI | MODERNA INC | N/A | 12.15B | ||
| 0QF.DE | MODERNA INC | N/A | 11.34B | ||
| BIO.DE | BIOTEST AG | 23.86 | 1.61B | ||
| GLPG.AS | GALAPAGOS NV | 21.12 | 1.56B |
Related stock screener links
About TNG.PA
Company Profile
Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 158 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Company Info
TRANSGENE SA
400 Boulevard Gonthier d'Andernach, Parc d'Innovation - CS80166
Illkirch-Graffenstaden GRAND EST FR
Employees: 146
Company Website: https://www.transgene.fr
Investor Relations: http://www.transgene.fr/en/investors/
Phone: 33388279100
TRANSGENE SA / TNG.PA FAQ
What is the stock price of TRANSGENE SA today?
The current stock price of TNG.PA is 0.671 EUR. The price increased by 1.05% in the last trading session.
What is the ticker symbol for TRANSGENE SA stock?
The exchange symbol of TRANSGENE SA is TNG and it is listed on the Euronext Paris - Matif exchange.
On which exchange is TNG.PA stock listed?
TNG.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for TRANSGENE SA stock?
7 analysts have analysed TNG.PA and the average price target is 1.73 EUR. This implies a price increase of 158.42% is expected in the next year compared to the current price of 0.671. Check the TRANSGENE SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TRANSGENE SA worth?
TRANSGENE SA (TNG.PA) has a market capitalization of 88.77M EUR. This makes TNG.PA a Micro Cap stock.
How many employees does TRANSGENE SA have?
TRANSGENE SA (TNG.PA) currently has 146 employees.
What are the support and resistance levels for TRANSGENE SA (TNG.PA) stock?
TRANSGENE SA (TNG.PA) has a support level at 0.66 and a resistance level at 0.67. Check the full technical report for a detailed analysis of TNG.PA support and resistance levels.
Is TRANSGENE SA (TNG.PA) expected to grow?
The Revenue of TRANSGENE SA (TNG.PA) is expected to decline by -44.69% in the next year. Check the estimates tab for more information on the TNG.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TRANSGENE SA (TNG.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TNG.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TNG.PA, evaluating the profitability, health, valuation and growth aspects
- TRANSGENE SA (TNG.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TRANSGENE SA (TNG.PA) Sales and EPS estimates to see what analysts future expectations are.
- TRANSGENE SA (TNG.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TRANSGENE SA (TNG.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TRANSGENE SA (TNG.PA) Stock Chart to make your own analysis
- TRANSGENE SA (TNG.PA) Latest news and press-releases to stay up to date.
Does TRANSGENE SA (TNG.PA) stock pay dividends?
TNG.PA does not pay a dividend.
When does TRANSGENE SA (TNG.PA) report earnings?
TRANSGENE SA (TNG.PA) will report earnings on 2025-03-27, after the market close.
What is the Price/Earnings (PE) ratio of TRANSGENE SA (TNG.PA)?
TRANSGENE SA (TNG.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).
TNG.PA Technical Analysis
TNG.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TNG.PA. Both the profitability and financial health of TNG.PA have multiple concerns.
TNG.PA Financial Highlights
Over the last trailing twelve months TNG.PA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 32.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.99% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TNG.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TNG.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 28% and a revenue growth -44.69% for TNG.PA